Cognition Therapeutics (CGTX) Interest & Investment Income (2023 - 2026)

Cognition Therapeutics (CGTX) has reported Interest & Investment Income for 4 consecutive years, with -$3000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Interest & Investment Income changed 0.0% year-over-year to -$3000.0 in Q2 2026; TTM through Jun 2026 was -$13000.0, a 18.75% increase from a year earlier, with the FY2025 full-year figure at -$13000.0, up 48.0% from the prior year.
• Interest & Investment Income was -$3000.0 for Q2 2026 at Cognition Therapeutics, up from -$5000.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at -$2000.0 in Q3 2023 and troughed at -$10000.0 in Q1 2024.
• A 4-year average of -$5250.0 and a median of -$5000.0 in 2024 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income sank 50.0% in 2024 and surged 57.14% in 2025, its largest moves.
• Over 4 years, Interest & Investment Income stood at -$9000.0 in 2023, then soared by 44.44% to -$5000.0 in 2024, then changed by 0.0% to -$5000.0 in 2025, then surged by 40.0% to -$3000.0 in 2026.
• The last three Interest & Investment Income figures came in at -$3000.0 (Q2 2026), -$5000.0 (Q1 2026), and -$5000.0 (Q4 2025), per Business Quant data.